Source: BusinessWire — 2026-07-22
Summary
Fishbone Advisors surveyed 75 institutional investors (76% long-only, 15% hedge fund, 9% sell-side; median equity AUM of $1.9B) between June 4-12, 2026, and found that across every healthcare subsector, 48-67% of investors believe management overemphasizes AI relative to its actual financial contribution. Six months after the same question was first asked, AI still hasn't registered as a material valuation driver in any healthcare subsector — with expectations for AI's three-year valuation impact ranging from 66% in biotechnology down to 20% in medical equipment, and payer/provider expectations actually falling 14 points over that period. The report's core message to healthcare executives: say less about AI, prove more.
Key Takeaways
- Survey base: 75 institutional investors (76% long-only, 15% hedge fund, 9% sell-side), median equity AUM of $1.9B, surveyed June 4-12, 2026, plus supplemental in-depth interviews — a specialist, buy-side-heavy sample, not a retail-investor poll.
- Headline finding: 48-67% of investors across every healthcare subsector say management teams overemphasize AI relative to its actual measured contribution to the business — the range spans the five subsectors covered (biotech, pharma, life sciences tools & services, payers & providers, and equipment & supplies).
- AI still hasn't become a material driver of valuation in any healthcare subsector, unchanged from when Fishbone asked the identical question six months earlier — this is a retest, not a one-off snapshot, so the finding is about persistence of skepticism, not a single data point.
- Subsector split on three-year outlook: biotechnology investors are most bullish on AI eventually mattering for valuation (66% expect significant influence within three years) versus medical equipment investors, the least bullish (20%). Payers and providers saw the biggest swing — expectations there fell 14 points to 34% over the six months.
- Specialist healthcare investors are notably more skeptical than generalists: only 33% of healthcare specialists expect AI to significantly influence valuations within three years, versus 51% of generalist investors — the people who know the sector best are the least convinced.
- The report's explicit recommendation to healthcare company management: talk about AI less, and demonstrate financial impact more — the opposite of the current boardroom instinct to lead earnings calls with AI narrative.
Reel Script
Hook (16s / 37 words) Two out of every three institutional investors in biotech think their portfolio companies are overselling AI on earnings calls. Not skeptics on the internet — professional money managers with real capital on the line, surveyed twice, six months apart, with the same answer both times.
Core Concept (50s / 112 words) Fishbone Advisors runs a recurring survey of institutional healthcare investors — people who manage real portfolios, median fund size close to two billion dollars — asking a specific, repeatable question: does management's AI talk match AI's actual financial impact on the business? They surveyed 75 investors in June, the same cohort profile they surveyed six months earlier, so this isn't one opinion poll — it's a retest designed to catch a trend. The result held steady both times: across every healthcare subsector they track — biotech, pharma, life sciences tools, payers and providers, medical equipment — 48 to 67% of investors say management is overemphasizing AI relative to what it's actually contributing financially.
Hands-On (55s / 128 words) The subsector breakdown is the part worth screenshotting. Ask investors "will AI meaningfully move valuation within three years" and biotech comes in highest at 66% saying yes — makes sense, AI-driven drug discovery has the clearest story. Medical equipment comes in lowest, just 20%. Payers and providers actually got more skeptical over the six months, dropping 14 points to 34% expecting real valuation impact. And here's the number that stings the most for AI marketers: healthcare specialist investors, the ones who understand the sector cold, are less convinced than generalists — 33% versus 51%. The people closest to the data are the most skeptical of the pitch, not the least.
Takeaway (23s / 53 words) The gap between AI messaging and AI's measured financial contribution is now a repeatedly-measured number, not a vibe. If you're building or pitching healthcare AI, the professional money is telling you directly: fewer AI slides, more attributable revenue or cost numbers on the next earnings call.